Top Telehealth Companies With Best Stability & Growth (902)

Strong Revenue Growth: Full-year FY2026 revenue rose 13% year over year to $644.9M, indicating continued expansion at scale. Quarterly performance varied, but the annual trajectory remained positive.

Healthy Cash Flow: Operating and free cash flow each increased 19% in FY2026 to $326.5M and $317.5M, respectively. This underscores strong cash generation alongside growth.

Strong Market Position & Advantage: The platform reports 3M+ members with 85%+ of U.S. physicians, and Q4 FY2026 set a record with 800,000+ active prescribers using workflow tools. Nearly half of these prescribers engaged with clinical AI features.

Profitability: Profitability is described as sustained since 2023 while the company continues to scale, pointing to durable unit economics. Company updates also indicate cash‑flow positivity and that efficiency targets such as the Rule of 40 have been surpassed.

Strong Revenue Growth: Revenue growth is characterized as strong over multiple years with momentum continuing into 2026. Acceleration is described alongside expansion in provider supply and booking channels.

Strategic Partnerships: New distribution and integrations, including embedded real‑time booking on Yelp and a payer partnership, broaden patient access points and reinforce growth. These partnerships extend reach beyond the core site into high‑traffic consumer and member channels.

Market Expansion: Nationwide availability is promoted on care pages and the iOS App Store listing, indicating coverage in all 50 states and signaling continued geographic reach. Hiring signals and a move into a larger office further suggest expanding operational presence.

Innovation-Driven Growth: Recent product updates—Spanish-language app support and an EHR-integrated AI medical scribe announced in June–July 2026—show ongoing investment in platform capabilities. The cadence of dated releases points to active development and product velocity.

Diversified Revenue Streams: The launch of insurance-based, in‑network plans (announced May 20, 2025; page updated July 14, 2026) reflects movement beyond a cash‑pay model. This expansion of payer channels indicates efforts to broaden how revenue is generated.

Strong Revenue Growth: Independent analysis indicates revenue reaccelerated in 2024 with GLP‑1 weight‑management becoming the primary engine. Signals since late 2023 point to material momentum tied to the Ro Body program.

Strategic Partnerships: Integrations with Eli Lilly (LillyDirect Zepbound vials) and Novo Nordisk (Wegovy pill launch and multi‑month subscription program) broaden branded access and price positioning on Ro’s platform. These manufacturer ties are presented as key levers for authentic supply and scaled distribution.

Market Expansion: Participation in the nationwide launch of the Wegovy pill and development of insurance‑navigation tools expand the GLP‑1 channel and lower access frictions. Movement into employer and health‑plan pathways aims to extend reach beyond purely cash‑pay dynamics.

Strong Revenue Growth: Independent estimates indicate annualized gross revenue roughly doubled in 2024, signaling rapid top‑line expansion. This momentum aligns with broader scale indicators such as rising session volume and network capacity.

Market Expansion: Therapy coverage reached all 50 states and D.C. in 2024, with psychiatry expanded nationwide by 2025. Capacity signals like millions of cumulative sessions and large weekly appointment availability underscore geographic and operational scale.

Strategic Partnerships: New and expanding payer and benefit relationships, including the Sidecar Health collaboration announced in late 2025, broaden distribution and access. Additional channel activity and partner listings point to growing reach through third‑party ecosystems.

Investor Backing & Capital Strength: Multiple late‑stage rounds since 2024, including a $72M Series C in 2025 and a reported $162M total raised, indicate robust external support and runway.

Strategic Partnerships: Named deals in 2026 with Zurich (UK), Transamerica, and Equitable, alongside claims of working with 8 of the top 10 U.S. life insurers, broaden access to millions of beneficiaries. Zurich UK provides independent confirmation of rollout.

Market Expansion: Geographic availability has widened from the U.S. into Canada and the U.K., supported by insurer and bank launches in 2025–2026. This expansion increases potential reach across North America and Europe.

Market Expansion: Geographic reach has broadened to about 25 U.S. states for Care+ in‑home preventive visits, with coverage spanning Medicare, Medicaid, and Marketplace lines of business. Materials from 2023–2026 indicate a step‑up from 5 states to roughly half the nation by February 2026.

Strategic Partnerships: Collaborations with payers and providers are expanding, exemplified by Blue Cross Blue Shield of Michigan/Blue Care Network offering in‑home diabetic retinal screenings starting April 1, 2026 and UCI Health signaling plans to grow joint programs. Additional references highlight added payer/provider relationships through 2025–2026.

Investor Backing & Capital Strength: A $55 million Series B closed on May 15, 2025 led by General Catalyst with participation from a16z Bio + Health and others, providing fuel to scale at‑home services. Third‑party trackers and coverage cite total funding in the roughly $92.6 million to ~$125 million range.

Strong Revenue Growth: Repeated inclusion on the Inc. 5000 list in 2024 and 2025 indicates multi‑year revenue expansion. This sustained recognition points to continued top‑line momentum through mid‑2026.

Innovation-Driven Growth: Recent AI launches for ABA operations (e.g., an AI dashboard and AI‑assisted documentation) reflect active product investment. This cadence suggests a focus on differentiation and upsell potential across the platform.

Market Expansion: Expansion via acquisition—most notably the August 2025 purchase of Joshin—positions the portfolio to cover broader neurodiversity and disability support. Partnerships and integrations alongside broad employer, education, and provider adoption indicate a scaling footprint.

Investor Backing & Capital Strength: Capital raised includes a $35M Series A (2024), $70M Series B (2025), and $100M Series C (2026), with reports of a roughly $1.75B valuation. Consistent step-ups in round size and total funding signal traction and confidence to fuel scale.

Profitability: Profitability is reported for 2025, unusual among digital health peers at this stage. This indicates operating leverage with payer reimbursement working as intended.

Strategic Partnerships: Payer coverage spans national commercial plans plus Medicare and Medicaid, a key lever for patient acquisition and revenue consistency in virtual care. Broad distribution is reflected in nationwide availability and hundreds of thousands of patients served.

Investor Backing & Capital Strength: Recent late-stage financings — a February 2026 Series D followed by a May 2026 Series E at a higher stated valuation — indicate strong capital access and confidence. Disclosures cite prominent investors and a sizable valuation step‑up, providing resources to scale.

Market Expansion: Company communications describe reach to almost 800 employer clients and multi‑million member coverage, signaling a broader commercial footprint across the employer market. New feature releases such as Predictive Outreach and added distribution channels support this expanding reach.

Strategic Partnerships: Collaborations announced in 2026 with Priority Health and Atlantic Health extend distribution to commercial employer groups through plan and health‑system channels. These partnerships reinforce access to steer members toward higher‑performing providers.

Strong Hiring & Retention: Active recruiting is evident with 20+ open roles on Indeed across multiple states and functions, alongside a LinkedIn size band of 51–200 and recent activity signaling team buildout. Role postings span therapists, a remote RN health advocate, and operations/partnerships positions, indicating capacity expansion.

Market Expansion: Medicare-covered virtual therapy is marketed across all 50 states with state-by-state pages and booking via channels like Zocdoc, pointing to an enlarging go-to-market footprint. Site and blog updates through 2025–2026 and a market-launch role (e.g., Philadelphia) further support ongoing geographic growth.

Strategic Partnerships: A publicly announced collaboration with Advanced Nursing & Home Care and recent LinkedIn partnership/event posts suggest growing referral networks. These signals align with efforts to embed within senior-care ecosystems to broaden distribution.

Market Expansion: New enterprise engagements in March 2026 and references to serving more than 26 million individuals across the U.S. and Latin America point to a widening commercial footprint. Activity spanning payers, an employer‑focused care management organization, and Latin American markets indicates broadened reach.

Innovation-Driven Growth: Launch of an AI‑powered Navigator for health plans, new collaboration features tied to the 2024 rebrand, and additional AI agents signal active product expansion. These moves reflect continued investment aligned to payer and ASO workflows.

Strategic Partnerships: Collaborations with Google Cloud and longstanding payer/provider ties (e.g., Horizon) strengthen distribution and technical credibility. Partnership announcements and an active press cadence suggest enterprise‑scale deployments and momentum.

Investor Backing & Capital Strength: Recent financing includes a June 2024 seed and an October 2025 $15.5M Series A led by Costanoa with Town Hall Ventures and Khosla, positioned to fund hiring, product, and market expansion. Public investor and media materials describe this capital as intended to scale operations and partnerships.

Market Expansion: Operations are described as growing beyond New York into New Jersey and Ohio, with compliance entities in multiple states and localized, multilingual school pages signaling multi‑district deployment. District approvals and company updates point to a widening on‑the‑ground footprint.

Strategic Partnerships: Public district materials (e.g., Millville Public Schools and Upper Deerfield Township in NJ) announce Marble programs, indicating active school partnerships. Company communications highlight a school‑centered model built specifically for schools, reinforcing this partnership‑led growth.

Investor Backing & Capital Strength: Back-to-back raises—a $32M Series A (2024) and a $50M Series B (2025)—are noted as fuel to hire, build, and scale. The Series B was led by Key1 Capital with participation from existing investors, signaling strong capital support.

Product Line Growth: New offerings such as “Zoe for HR” launched on June 11, 2026, along with AI-powered claims analytics and other enhancements, indicate continued investment and iteration. These additions expand functionality beyond core navigation into analytics and cost containment.

Strategic Partnerships: Collaborations and channels including TriNet, PrismHR, and joining the Workday Wellness Program extend distribution into employer and PEO ecosystems. Additional relationships (e.g., Homethrive) broaden the platform’s scope and access.